APLS241115P21000
- 0.05
- 0.000.00%
Apellis Pharmaceuticals Newsroom
Apellis Pharmaceuticals Is Maintained at Outperform by Baird
Apellis Pharmaceuticals Analyst Ratings
UBS Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $45
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $30 to $55
Earnings Call: Apellis Pharmaceuticals Q3 2024 Results Show Promise
RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $24
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
Apellis Pharmaceuticals Price Target Cut to $30.00/Share From $43.00 by Wells Fargo
Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $40 From $65, Maintains Outperform Rating
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $30 to $75
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Apellis Pharmaceuticals Is Maintained at Buy by B of A Securities
Apellis Pharmaceuticals (APLS) Receives a Hold From Piper Sandler
Strategic Positioning and Strong Efficacy Drive 'Buy' Rating for Apellis Pharmaceuticals
Apellis Pharmaceuticals: Hold Rating Amid Revenue Miss and Financial Challenges
Apellis Pharmaceuticals Reports Revenue Growth Amid Ongoing Investments
Express News | Apellis Pharmaceuticals Inc : Piper Sandler Cuts Target Price to $32 From $40
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript Summary
Strategic Initiatives and Long-Term Growth Potential of Apellis Pharmaceuticals